You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameNefazodone
Accession NumberDB01149  (APRD00402)
TypeSmall Molecule
GroupsApproved, Withdrawn
DescriptionNefazodone hydrochloride (trade name Serzone) is an antidepressant drug marketed by Bristol-Myers Squibb. Its sale was discontinued in 2003 in some countries, due to the small possibility of hepatic (liver) injury, which could lead to the need for a liver transplant, or even death. The incidence of severe liver damage is approximately 1 in 250,000 to 300,000 patient-years. On May 20, 2004, Bristol-Myers Squibb discontinued the sale of Serzone in the United States. [Wikipedia]
Structure
Thumb
Synonyms
1-(3-(4-(m-Chlorophenyl)-1-piperazinyl)propyl)-3-ethyl-4-(2-phenoxyethyl)-delta2-1,2,4-triazolin-5-one
Nefazodona
Nefazodone
Nefazodonum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Lin-nefazodoneTablet200 mgOralLinson Pharma Co.2000-09-112003-11-28Canada
Lin-nefazodoneTablet50 mgOralLinson Pharma Co.2000-09-112003-11-28Canada
Lin-nefazodoneTablet100 mgOralLinson Pharma Co.2000-09-112003-11-28Canada
Lin-nefazodoneTablet150 mgOralLinson Pharma Co.2000-09-112003-11-28Canada
Serzone-5ht2Tablet150 mgOralBristol Myers Squibb Canada1994-12-312003-11-28Canada
Serzone-5ht2Tablet100 mgOralBristol Myers Squibb Canada1994-12-312003-11-28Canada
Serzone-5ht2Tablet200 mgOralBristol Myers Squibb Canada1994-12-312003-11-28Canada
Serzone-5ht2Tablet50 mgOralBristol Myers Squibb Canada1997-07-162003-11-28Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Nefazodone HydrochlorideTablet150 mg/1OralRebel Distributors Corp2003-09-16Not applicableUs
Nefazodone HydrochlorideTablet100 mg/1OralTeva Pharmaceuticals USA Inc2003-09-16Not applicableUs
Nefazodone HydrochlorideTablet250 mg/1OralAv Kare, Inc.2013-07-30Not applicableUs
Nefazodone HydrochlorideTablet50 mg/1OralTeva Pharmaceuticals USA Inc2003-09-16Not applicableUs
Nefazodone HydrochlorideTablet200 mg/1OralRebel Distributors Corp2003-09-16Not applicableUs
Nefazodone HydrochlorideTablet200 mg/1OralTeva Pharmaceuticals USA Inc2003-09-16Not applicableUs
Nefazodone HydrochlorideTablet50 mg/1OralAv Kare, Inc.2013-12-16Not applicableUs
Nefazodone HydrochlorideTablet100 mg/1OralSTAT Rx USA LLC2010-08-18Not applicableUs
Nefazodone HydrochlorideTablet250 mg/1OralRebel Distributors Corp2003-09-16Not applicableUs
Nefazodone HydrochlorideTablet250 mg/1OralTeva Pharmaceuticals USA Inc2003-09-16Not applicableUs
Nefazodone HydrochlorideTablet100 mg/1OralRebel Distributors Corp2003-09-16Not applicableUs
Nefazodone HydrochlorideTablet100 mg/1OralREMEDYREPACK INC.2011-06-082016-10-13Us
Nefazodone HydrochlorideTablet150 mg/1OralTeva Pharmaceuticals USA Inc2003-09-16Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
DutoninNot Available
SerzoneNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Nefazodone Hydrochloride
82752-99-6
Thumb
  • InChI Key: DYCKFEBIOUQECE-UHFFFAOYSA-N
  • Monoisotopic Mass: 505.201130739
  • Average Mass: 506.468
DBSALT000406
Categories
UNII59H4FCV1TF
CAS number83366-66-9
WeightAverage: 470.007
Monoisotopic: 469.224453
Chemical FormulaC25H32ClN5O2
InChI KeyVRBKIVRKKCLPHA-UHFFFAOYSA-N
InChI
InChI=1S/C25H32ClN5O2/c1-2-24-27-31(25(32)30(24)18-19-33-23-10-4-3-5-11-23)13-7-12-28-14-16-29(17-15-28)22-9-6-8-21(26)20-22/h3-6,8-11,20H,2,7,12-19H2,1H3
IUPAC Name
1-{3-[4-(3-chlorophenyl)piperazin-1-yl]propyl}-3-ethyl-4-(2-phenoxyethyl)-4,5-dihydro-1H-1,2,4-triazol-5-one
SMILES
CCC1=NN(CCCN2CCN(CC2)C2=CC(Cl)=CC=C2)C(=O)N1CCOC1=CC=CC=C1
Pharmacology
IndicationFor the treatment of depression.
Structured Indications
PharmacodynamicsNefazodone, an antidepressant synthetically derived phenylpiperazine, is used to treat major depression. Although it is structurally similar to trazodone, nefazodone has a mechanism of action different from other antidepressants and, hence, lacks the risk for major cardiovascular toxicity seen with tricyclics and insomnia and inhibition of REM sleep seen with the selective serotonin reuptake inhibitors.
Mechanism of actionWithin the serotonergic system, nefazodone acts as an antagonist at type 2 serotonin (5-HT2) post-synaptic receptors and, like fluoxetine-type antidepressants, inhibits pre-synaptic serotonin (5-HT) reuptake. These mechanisms increase the amount of serotonin available to interact with 5-HT receptors. Within the noradrenergic system, nefazodone inhibits norepinephrine uptake minimally. Nefazodone also antagonizes alpha(1)-adrenergic receptors, producing sedation, muscle relaxation, and a variety of cardiovascular effects. Nefazodone's affinity for benzodiazepine, cholinergic, dopaminergic, histaminic, and beta or alpha(2)-adrenergic receptors is not significant.
TargetKindPharmacological actionActionsOrganismUniProt ID
5-hydroxytryptamine receptor 2AProteinyes
antagonist
HumanP28223 details
5-hydroxytryptamine receptor 2CProteinyes
antagonist
HumanP28335 details
Sodium-dependent serotonin transporterProteinyes
inhibitor
HumanP31645 details
5-hydroxytryptamine receptor 1AProteinyes
antagonist
HumanP08908 details
Sodium-dependent noradrenaline transporterProteinyes
inhibitor
HumanP23975 details
Sodium-dependent dopamine transporterProteinunknown
inhibitor
HumanQ01959 details
Alpha-1B adrenergic receptorProteinunknown
other/unknown
HumanP35368 details
Alpha-2A adrenergic receptorProteinunknown
antagonist
HumanP08913 details
Alpha-1A adrenergic receptorProteinno
antagonist
HumanP35348 details
Related Articles
AbsorptionNefazodone is rapidly and completely absorbed. Its absolute bioavailability is low (about 20%).
Volume of distribution
  • 0.22 to 0.87 L/kg
Protein bindingGreater than 99% (in vitro, human plasma proteins).
Metabolism

Hepatic.

SubstrateEnzymesProduct
Nefazodone
hydroxynefazodoneDetails
Route of eliminationNefazodone is extensively metabolized after oral administration by n-dealkylation and aliphatic and aromatic hydroxylation, and less than 1% of administered nefazodone is excreted unchanged in urine.
Half life2-4 hours
ClearanceNot Available
ToxicityCases of life-threatening hepatic failure have been reported in patients treated with nefazodone.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when 1,1,1,2 Tetrafluoroethane is combined with Nefazodone.Investigational
1,10-PhenanthrolineThe serum concentration of Nefazodone can be increased when it is combined with 1,10-Phenanthroline.Experimental
16-BromoepiandrosteroneThe serum concentration of 16-Bromoepiandrosterone can be increased when it is combined with Nefazodone.Investigational
19-norandrostenedioneThe serum concentration of 19-norandrostenedione can be increased when it is combined with Nefazodone.Experimental, Illicit
3,4-DichloroisocoumarinThe serum concentration of Nefazodone can be increased when it is combined with 3,4-Dichloroisocoumarin.Experimental
4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDEThe serum concentration of Nefazodone can be increased when it is combined with 4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDE.Experimental
4-AndrostenedioneThe serum concentration of 4-Androstenedione can be increased when it is combined with Nefazodone.Experimental, Illicit
5-androstenedioneThe serum concentration of 5-androstenedione can be increased when it is combined with Nefazodone.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Nefazodone.Experimental
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the serotonergic activities of Nefazodone.Experimental
AbirateroneThe serum concentration of Nefazodone can be increased when it is combined with Abiraterone.Approved
AcarboseNefazodone may increase the hypoglycemic activities of Acarbose.Approved, Investigational
AcebutololThe serum concentration of Acebutolol can be decreased when it is combined with Nefazodone.Approved
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Nefazodone.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Nefazodone is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Nefazodone is combined with Aceprometazine.Approved
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Nefazodone.Approved
AcetophenazineThe risk or severity of adverse effects can be increased when Nefazodone is combined with Acetophenazine.Approved
Acetylsalicylic acidNefazodone may increase the antiplatelet activities of Acetylsalicylic acid.Approved, Vet Approved
AdinazolamThe metabolism of Adinazolam can be decreased when combined with Nefazodone.Approved
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Nefazodone.Investigational
AfatinibThe serum concentration of Afatinib can be decreased when it is combined with Nefazodone.Approved
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Nefazodone.Approved, Investigational
AlbendazoleThe metabolism of Albendazole can be decreased when combined with Nefazodone.Approved, Vet Approved
AlbiglutideNefazodone may increase the hypoglycemic activities of Albiglutide.Approved
AlclometasoneThe metabolism of Alclometasone can be decreased when combined with Nefazodone.Approved
AldosteroneThe serum concentration of Aldosterone can be decreased when it is combined with Nefazodone.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Nefazodone.Vet Approved
AlfentanilThe metabolism of Alfentanil can be decreased when combined with Nefazodone.Approved, Illicit
AlfuzosinThe serum concentration of Alfuzosin can be increased when it is combined with Nefazodone.Approved, Investigational
AliskirenThe metabolism of Aliskiren can be decreased when combined with Nefazodone.Approved, Investigational
AlitretinoinThe serum concentration of Alitretinoin can be decreased when it is combined with Nefazodone.Approved, Investigational
AllylestrenolThe metabolism of Allylestrenol can be decreased when combined with Nefazodone.Approved
AlmotriptanThe serum concentration of Almotriptan can be increased when it is combined with Nefazodone.Approved, Investigational
AlogliptinThe serum concentration of Nefazodone can be increased when it is combined with Alogliptin.Approved
AlosetronThe serum concentration of Alosetron can be increased when it is combined with Nefazodone.Approved, Withdrawn
Alpha-1-proteinase inhibitorThe serum concentration of Nefazodone can be increased when it is combined with Alpha-1-proteinase inhibitor.Approved
AlphacetylmethadolAlphacetylmethadol may increase the serotonergic activities of Nefazodone.Experimental, Illicit
AlprazolamThe metabolism of Alprazolam can be decreased when combined with Nefazodone.Approved, Illicit, Investigational
AlprenololThe serum concentration of Alprenolol can be increased when it is combined with Nefazodone.Approved, Withdrawn
AmbrisentanThe metabolism of Ambrisentan can be decreased when combined with Nefazodone.Approved, Investigational
AmbroxolThe metabolism of Ambroxol can be decreased when combined with Nefazodone.Approved
AmcinonideThe serum concentration of Amcinonide can be increased when it is combined with Nefazodone.Approved
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Nefazodone.Approved, Withdrawn
AminophyllineThe metabolism of Aminophylline can be decreased when combined with Nefazodone.Approved
AmiodaroneThe metabolism of Nefazodone can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Nefazodone is combined with Amisulpride.Approved, Investigational
AmitriptylineThe metabolism of Amitriptyline can be decreased when combined with Nefazodone.Approved
AmlodipineThe metabolism of Amlodipine can be decreased when combined with Nefazodone.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Nefazodone.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Nefazodone.Approved
AmperozideThe risk or severity of adverse effects can be increased when Nefazodone is combined with Amperozide.Experimental
AmprenavirThe serum concentration of Nefazodone can be increased when it is combined with Amprenavir.Approved
AnecortaveThe serum concentration of Anecortave can be increased when it is combined with Nefazodone.Investigational
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Nefazodone.Approved
Antithrombin III humanThe serum concentration of Nefazodone can be increased when it is combined with Antithrombin III human.Approved
Aop200704The serum concentration of Aop200704 can be increased when it is combined with Nefazodone.Investigational
ApixabanThe serum concentration of Nefazodone can be increased when it is combined with Apixaban.Approved
ApremilastThe metabolism of Apremilast can be decreased when combined with Nefazodone.Approved, Investigational
AprepitantThe serum concentration of Nefazodone can be increased when it is combined with Aprepitant.Approved, Investigational
AprotininThe serum concentration of Nefazodone can be increased when it is combined with Aprotinin.Approved, Withdrawn
ArgatrobanThe serum concentration of Nefazodone can be increased when it is combined with Argatroban.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Nefazodone.Approved, Investigational
ArotinololThe serum concentration of Arotinolol can be increased when it is combined with Nefazodone.Approved
Arsenic trioxideThe serum concentration of Arsenic trioxide can be decreased when it is combined with Nefazodone.Approved, Investigational
ArtemetherThe metabolism of Artemether can be decreased when combined with Nefazodone.Approved
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Nefazodone.Approved
AsenapineThe metabolism of Asenapine can be decreased when combined with Nefazodone.Approved
AstemizoleThe serum concentration of Astemizole can be increased when it is combined with Nefazodone.Approved, Withdrawn
AsunaprevirThe serum concentration of Nefazodone can be increased when it is combined with Asunaprevir.Approved, Investigational
AtazanavirThe serum concentration of Nefazodone can be increased when it is combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Atenolol can be decreased when it is combined with Nefazodone.Approved
AtomoxetineThe metabolism of Nefazodone can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe metabolism of Atorvastatin can be decreased when combined with Nefazodone.Approved
AvanafilThe serum concentration of Avanafil can be increased when it is combined with Nefazodone.Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Nefazodone.Approved, Investigational
AzaperoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Azaperone.Vet Approved
AzelastineThe metabolism of Azelastine can be decreased when combined with Nefazodone.Approved
AzithromycinThe metabolism of Azithromycin can be decreased when combined with Nefazodone.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Nefazodone.Approved
BanoxantroneThe metabolism of Banoxantrone can be decreased when combined with Nefazodone.Investigational
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Nefazodone.Illicit
BarnidipineThe serum concentration of Barnidipine can be increased when it is combined with Nefazodone.Approved
BatimastatThe serum concentration of Nefazodone can be increased when it is combined with Batimastat.Experimental
BeclomethasoneThe serum concentration of Beclomethasone can be increased when it is combined with Nefazodone.Investigational
Beclomethasone dipropionateThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Nefazodone.Approved, Investigational
BedaquilineThe serum concentration of Bedaquiline can be increased when it is combined with Nefazodone.Approved
BefunololThe serum concentration of Befunolol can be increased when it is combined with Nefazodone.Experimental
BenazeprilThe serum concentration of Nefazodone can be increased when it is combined with Benazepril.Approved, Investigational
BendroflumethiazideNefazodone may increase the hyponatremic activities of Bendroflumethiazide.Approved
BenmoxinBenmoxin may increase the serotonergic activities of Nefazodone.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Nefazodone is combined with Benperidol.Investigational
BenzamidineThe serum concentration of Nefazodone can be increased when it is combined with Benzamidine.Experimental
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Nefazodone.Approved
BenzphetamineThe metabolism of Benzphetamine can be decreased when combined with Nefazodone.Approved, Illicit
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Nefazodone.Approved
BetamethasoneThe serum concentration of Betamethasone can be decreased when it is combined with Nefazodone.Approved, Vet Approved
BetaxololThe metabolism of Nefazodone can be decreased when combined with Betaxolol.Approved
BevantololThe serum concentration of Bevantolol can be increased when it is combined with Nefazodone.Approved
BexaroteneThe metabolism of Bexarotene can be decreased when combined with Nefazodone.Approved, Investigational
BezafibrateThe metabolism of Bezafibrate can be decreased when combined with Nefazodone.Approved
BezitramideBezitramide may increase the serotonergic activities of Nefazodone.Experimental, Illicit, Withdrawn
Bi201335The serum concentration of Nefazodone can be increased when it is combined with Bi201335.Investigational
BicalutamideThe metabolism of Bicalutamide can be decreased when combined with Nefazodone.Approved
BifeprunoxThe risk or severity of adverse effects can be increased when Nefazodone is combined with Bifeprunox.Investigational
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Nefazodone.Approved
BivalirudinThe serum concentration of Nefazodone can be increased when it is combined with Bivalirudin.Approved, Investigational
BoceprevirThe serum concentration of Nefazodone can be increased when it is combined with Boceprevir.Approved
BopindololThe serum concentration of Bopindolol can be increased when it is combined with Nefazodone.Approved
BortezomibThe serum concentration of Bortezomib can be increased when it is combined with Nefazodone.Approved, Investigational
BosentanThe serum concentration of Nefazodone can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Nefazodone.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Nefazodone.Approved
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Nefazodone.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Nefazodone.Approved
BrinzolamideThe serum concentration of Brinzolamide can be increased when it is combined with Nefazodone.Approved
BromazepamThe metabolism of Bromazepam can be decreased when combined with Nefazodone.Approved, Illicit
BromocriptineThe metabolism of Bromocriptine can be decreased when combined with Nefazodone.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Nefazodone is combined with Bromperidol.Investigational
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Nefazodone.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Nefazodone.Approved, Withdrawn
BucindololThe serum concentration of Bucindolol can be increased when it is combined with Nefazodone.Investigational
BudesonideThe serum concentration of Budesonide can be increased when it is combined with Nefazodone.Approved
BudesonideThe metabolism of Budesonide can be decreased when combined with Nefazodone.Approved
BufuralolThe serum concentration of Bufuralol can be increased when it is combined with Nefazodone.Experimental, Investigational
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Nefazodone.Approved, Investigational
BupranololThe serum concentration of Bupranolol can be increased when it is combined with Nefazodone.Approved
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Nefazodone.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Bupropion can be decreased when combined with Nefazodone.Approved
BuspironeBuspirone may increase the serotonergic activities of Nefazodone.Approved, Investigational
BusulfanThe metabolism of Busulfan can be decreased when combined with Nefazodone.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Nefazodone.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Nefazodone.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Nefazodone.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Nefazodone.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Nefazodone.Approved, Illicit
ButorphanolButorphanol may increase the serotonergic activities of Nefazodone.Approved, Illicit, Vet Approved
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Nefazodone.Approved
CabergolineThe metabolism of Cabergoline can be decreased when combined with Nefazodone.Approved
CabozantinibThe serum concentration of Cabozantinib can be increased when it is combined with Nefazodone.Approved
CaffeineThe metabolism of Caffeine can be decreased when combined with Nefazodone.Approved
CalcitriolThe metabolism of Calcitriol can be decreased when combined with Nefazodone.Approved, Nutraceutical
CamptothecinThe serum concentration of Camptothecin can be decreased when it is combined with Nefazodone.Experimental
CanagliflozinThe metabolism of Canagliflozin can be decreased when combined with Nefazodone.Approved
CandoxatrilThe serum concentration of Nefazodone can be increased when it is combined with Candoxatril.Experimental
CandoxatrilatThe serum concentration of Nefazodone can be increased when it is combined with Candoxatrilat.Experimental
CaptoprilThe serum concentration of Nefazodone can be increased when it is combined with Captopril.Approved
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Nefazodone.Approved, Investigational
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Nefazodone.Approved
CarfentanilCarfentanil may increase the serotonergic activities of Nefazodone.Illicit, Vet Approved
CarfilzomibThe serum concentration of Carfilzomib can be decreased when it is combined with Nefazodone.Approved
CariprazineThe metabolism of Cariprazine can be decreased when combined with Nefazodone.Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Nefazodone.Approved
CaroxazoneCaroxazone may increase the serotonergic activities of Nefazodone.Withdrawn
CarteololThe serum concentration of Carteolol can be increased when it is combined with Nefazodone.Approved
CarvedilolThe metabolism of Carvedilol can be decreased when combined with Nefazodone.Approved, Investigational
CelecoxibThe metabolism of Celecoxib can be decreased when combined with Nefazodone.Approved, Investigational
CeliprololThe metabolism of Celiprolol can be decreased when combined with Nefazodone.Approved, Investigational
CephalexinThe metabolism of Cephalexin can be decreased when combined with Nefazodone.Approved, Vet Approved
CeritinibThe serum concentration of Ceritinib can be increased when it is combined with Nefazodone.Approved
CerivastatinThe metabolism of Cerivastatin can be decreased when combined with Nefazodone.Withdrawn
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Nefazodone.Approved
CevimelineThe metabolism of Cevimeline can be decreased when combined with Nefazodone.Approved
Chenodeoxycholic acidThe metabolism of Chenodeoxycholic acid can be decreased when combined with Nefazodone.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Nefazodone.Approved, Illicit, Vet Approved
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Nefazodone.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Nefazodone.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Nefazodone.Approved
ChloroquineThe metabolism of Chloroquine can be decreased when combined with Nefazodone.Approved, Vet Approved
ChlorothiazideNefazodone may increase the hyponatremic activities of Chlorothiazide.Approved, Vet Approved
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Nefazodone.Approved
ChlorpromazineThe metabolism of Chlorpromazine can be decreased when combined with Nefazodone.Approved, Vet Approved
ChlorpropamideNefazodone may increase the hypoglycemic activities of Chlorpropamide.Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Chlorprothixene.Approved, Withdrawn
ChlorthalidoneNefazodone may increase the hyponatremic activities of Chlorthalidone.Approved
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Nefazodone.Approved
CholecalciferolThe metabolism of Cholecalciferol can be decreased when combined with Nefazodone.Approved, Nutraceutical
ChymostatinThe serum concentration of Nefazodone can be increased when it is combined with Chymostatin.Experimental
CiclesonideThe metabolism of Ciclesonide can be decreased when combined with Nefazodone.Approved, Investigational
CilastatinThe serum concentration of Nefazodone can be increased when it is combined with Cilastatin.Approved
CilazaprilThe serum concentration of Nefazodone can be increased when it is combined with Cilazapril.Approved
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Nefazodone.Approved
CimetidineThe metabolism of Nefazodone can be decreased when combined with Cimetidine.Approved
CinacalcetThe metabolism of Cinacalcet can be decreased when combined with Nefazodone.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Nefazodone.Approved, Vet Approved
CiprofloxacinThe serum concentration of Ciprofloxacin can be decreased when it is combined with Nefazodone.Approved, Investigational
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Nefazodone.Approved, Investigational, Withdrawn
CisplatinThe serum concentration of Cisplatin can be decreased when it is combined with Nefazodone.Approved
CitalopramThe metabolism of Citalopram can be decreased when combined with Nefazodone.Approved
ClarithromycinThe metabolism of Clarithromycin can be decreased when combined with Nefazodone.Approved
ClemastineThe metabolism of Nefazodone can be decreased when combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Nefazodone.Approved
ClindamycinThe metabolism of Clindamycin can be decreased when combined with Nefazodone.Approved, Vet Approved
ClobazamThe metabolism of Clobazam can be decreased when combined with Nefazodone.Approved, Illicit
ClobetasolThe serum concentration of Clobetasol can be increased when it is combined with Nefazodone.Investigational
Clobetasol propionateThe serum concentration of Clobetasol propionate can be increased when it is combined with Nefazodone.Approved
ClocortoloneThe serum concentration of Clocortolone can be increased when it is combined with Nefazodone.Approved
ClofazimineThe metabolism of Clofazimine can be decreased when combined with Nefazodone.Approved, Investigational
ClofibrateThe metabolism of Clofibrate can be decreased when combined with Nefazodone.Approved
clomethiazoleThe metabolism of clomethiazole can be decreased when combined with Nefazodone.Investigational
ClomifeneThe serum concentration of Clomifene can be decreased when it is combined with Nefazodone.Approved, Investigational
ClomipramineThe metabolism of Clomipramine can be decreased when combined with Nefazodone.Approved, Vet Approved
ClonazepamThe metabolism of Clonazepam can be decreased when combined with Nefazodone.Approved, Illicit
ClonidineThe metabolism of Clonidine can be decreased when combined with Nefazodone.Approved
ClopidogrelThe metabolism of Clopidogrel can be decreased when combined with Nefazodone.Approved, Nutraceutical
ClorazepateThe metabolism of Clorazepate can be decreased when combined with Nefazodone.Approved, Illicit
ClotiazepamThe metabolism of Clotiazepam can be decreased when combined with Nefazodone.Approved, Illicit
ClotrimazoleThe metabolism of Nefazodone can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Clozapine can be decreased when combined with Nefazodone.Approved
CobicistatThe serum concentration of Nefazodone can be increased when it is combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Nefazodone.Approved
CocaineThe metabolism of Cocaine can be decreased when combined with Nefazodone.Approved, Illicit
CodeineThe metabolism of Codeine can be decreased when combined with Nefazodone.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Nefazodone.Approved
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Nefazodone.Approved, Investigational
Conjugated Equine EstrogensThe metabolism of Conjugated Equine Estrogens can be decreased when combined with Nefazodone.Approved
Cortisone acetateThe metabolism of Cortisone acetate can be decreased when combined with Nefazodone.Approved
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Nefazodone.Approved
CyamemazineThe risk or severity of adverse effects can be increased when Nefazodone is combined with Cyamemazine.Approved
CyclizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Nefazodone.Approved
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Nefazodone.Approved
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Nefazodone.Approved, Investigational
CyclosporineThe metabolism of Cyclosporine can be decreased when combined with Nefazodone.Approved, Investigational, Vet Approved
CyproheptadineThe therapeutic efficacy of Nefazodone can be decreased when used in combination with Cyproheptadine.Approved
CytarabineThe metabolism of Cytarabine can be decreased when combined with Nefazodone.Approved, Investigational
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Nefazodone.Approved
DabrafenibThe serum concentration of Nefazodone can be decreased when it is combined with Dabrafenib.Approved
DaclatasvirThe serum concentration of Daclatasvir can be increased when it is combined with Nefazodone.Approved
DactinomycinThe serum concentration of Dactinomycin can be decreased when it is combined with Nefazodone.Approved
DantroleneThe metabolism of Dantrolene can be decreased when combined with Nefazodone.Approved
DapagliflozinThe metabolism of Dapagliflozin can be decreased when combined with Nefazodone.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Nefazodone is combined with Dapiprazole.Approved
DapoxetineThe serum concentration of Dapoxetine can be increased when it is combined with Nefazodone.Investigational
DapsoneThe metabolism of Dapsone can be decreased when combined with Nefazodone.Approved, Investigational
DarifenacinThe metabolism of Darifenacin can be decreased when combined with Nefazodone.Approved, Investigational
DarunavirThe serum concentration of Nefazodone can be increased when it is combined with Darunavir.Approved
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Nefazodone.Approved
DasatinibThe serum concentration of Dasatinib can be increased when it is combined with Nefazodone.Approved, Investigational
DaunorubicinThe metabolism of Daunorubicin can be decreased when combined with Nefazodone.Approved
DebrisoquinThe serum concentration of Debrisoquin can be decreased when it is combined with Nefazodone.Approved
DeferasiroxThe serum concentration of Nefazodone can be decreased when it is combined with Deferasirox.Approved, Investigational
dehydroepiandrosterone sulfateThe serum concentration of dehydroepiandrosterone sulfate can be increased when it is combined with Nefazodone.Investigational
DelavirdineThe metabolism of Delavirdine can be decreased when combined with Nefazodone.Approved
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Nefazodone.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Nefazodone.Approved
DesipramineThe risk or severity of adverse effects can be increased when Nefazodone is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Nefazodone.Approved, Investigational
DesmopressinThe risk or severity of adverse effects can be increased when Nefazodone is combined with Desmopressin.Approved
DesoximetasoneThe serum concentration of Desoximetasone can be increased when it is combined with Nefazodone.Approved
Desoxycorticosterone acetateThe serum concentration of Desoxycorticosterone acetate can be increased when it is combined with Nefazodone.Approved
Desoxycorticosterone PivalateThe serum concentration of Desoxycorticosterone Pivalate can be increased when it is combined with Nefazodone.Experimental, Vet Approved
DesvenlafaxineThe metabolism of Desvenlafaxine can be decreased when combined with Nefazodone.Approved
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Nefazodone.Vet Approved
DexamethasoneThe metabolism of Dexamethasone can be decreased when combined with Nefazodone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe serum concentration of Dexamethasone isonicotinate can be increased when it is combined with Nefazodone.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Nefazodone.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Nefazodone.Approved, Vet Approved
DextromethorphanNefazodone may increase the serotonergic activities of Dextromethorphan.Approved
DextromoramideDextromoramide may increase the serotonergic activities of Nefazodone.Experimental, Illicit
DextropropoxypheneThe metabolism of Dextropropoxyphene can be decreased when combined with Nefazodone.Approved, Illicit, Withdrawn
DezocineDezocine may increase the serotonergic activities of Nefazodone.Approved
DiazepamThe metabolism of Diazepam can be decreased when combined with Nefazodone.Approved, Illicit, Vet Approved
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Nefazodone.Approved, Vet Approved
DicoumarolNefazodone may increase the anticoagulant activities of Dicoumarol.Approved
DienogestThe serum concentration of Dienogest can be increased when it is combined with Nefazodone.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Nefazodone.Approved
DifenoxinThe risk or severity of adverse effects can be increased when Difenoxin is combined with Nefazodone.Approved, Illicit
DiflorasoneThe serum concentration of Diflorasone can be increased when it is combined with Nefazodone.Approved
DifluocortoloneThe serum concentration of Difluocortolone can be increased when it is combined with Nefazodone.Approved
DifluprednateThe serum concentration of Difluprednate can be increased when it is combined with Nefazodone.Approved
DigitoxinThe metabolism of Digitoxin can be decreased when combined with Nefazodone.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Nefazodone.Approved
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Nefazodone.Approved, Illicit
DihydroergotamineThe metabolism of Dihydroergotamine can be decreased when combined with Nefazodone.Approved
DihydroetorphineDihydroetorphine may increase the serotonergic activities of Nefazodone.Experimental, Illicit
DihydromorphineDihydromorphine may increase the serotonergic activities of Nefazodone.Experimental, Illicit
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be decreased when it is combined with Nefazodone.Illicit
DiltiazemThe metabolism of Diltiazem can be decreased when combined with Nefazodone.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Nefazodone.Approved
DiphenhydramineThe metabolism of Nefazodone can be decreased when combined with Diphenhydramine.Approved
DiphenoxylateDiphenoxylate may increase the serotonergic activities of Nefazodone.Approved, Illicit
DipyridamoleThe serum concentration of Dipyridamole can be decreased when it is combined with Nefazodone.Approved
DisopyramideThe metabolism of Disopyramide can be decreased when combined with Nefazodone.Approved
DisulfiramThe metabolism of Disulfiram can be decreased when combined with Nefazodone.Approved
DocetaxelThe metabolism of Docetaxel can be decreased when combined with Nefazodone.Approved, Investigational
DofetilideThe serum concentration of Dofetilide can be increased when it is combined with Nefazodone.Approved
DolasetronThe metabolism of Dolasetron can be decreased when combined with Nefazodone.Approved
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Nefazodone.Approved, Investigational, Vet Approved
DonepezilThe metabolism of Donepezil can be decreased when combined with Nefazodone.Approved
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Nefazodone.Vet Approved
DorzolamideThe metabolism of Dorzolamide can be decreased when combined with Nefazodone.Approved
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Nefazodone.Approved
DoxepinThe metabolism of Doxepin can be decreased when combined with Nefazodone.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Nefazodone.Approved, Investigational
DoxorubicinThe metabolism of Doxorubicin can be decreased when combined with Nefazodone.Approved, Investigational
DoxycyclineThe metabolism of Nefazodone can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineThe risk or severity of adverse effects can be increased when Doxylamine is combined with Nefazodone.Approved, Vet Approved
DPDPEDPDPE may increase the serotonergic activities of Nefazodone.Investigational
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Nefazodone.Approved, Illicit
DronedaroneThe serum concentration of Dronedarone can be increased when it is combined with Nefazodone.Approved
DroperidolThe risk or severity of adverse effects can be increased when Nefazodone is combined with Droperidol.Approved, Vet Approved
DrospirenoneThe serum concentration of Drospirenone can be increased when it is combined with Nefazodone.Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Nefazodone.Experimental, Illicit
DulaglutideNefazodone may increase the hypoglycemic activities of Dulaglutide.Approved
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Nefazodone.Approved
DutasterideThe serum concentration of Dutasteride can be increased when it is combined with Nefazodone.Approved, Investigational
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Nefazodone.Approved
EcabetThe serum concentration of Nefazodone can be increased when it is combined with Ecabet.Approved, Investigational
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Nefazodone.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Nefazodone.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Nefazodone is combined with Ecopipam.Investigational
EdoxabanThe serum concentration of Nefazodone can be increased when it is combined with Edoxaban.Approved
EfavirenzThe metabolism of Efavirenz can be decreased when combined with Nefazodone.Approved, Investigational
ElafinThe serum concentration of Nefazodone can be increased when it is combined with Elafin.Investigational
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Nefazodone.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Nefazodone.Approved
ElvitegravirThe metabolism of Elvitegravir can be decreased when combined with Nefazodone.Approved
EmpagliflozinNefazodone may increase the hypoglycemic activities of Empagliflozin.Approved
EnalaprilThe serum concentration of Nefazodone can be increased when it is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe serum concentration of Nefazodone can be increased when it is combined with Enalaprilat.Approved
EnalkirenThe serum concentration of Nefazodone can be increased when it is combined with Enalkiren.Experimental
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Nefazodone.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Nefazodone.Approved, Investigational
EnzalutamideThe serum concentration of Nefazodone can be decreased when it is combined with Enzalutamide.Approved
EpinastineThe metabolism of Epinastine can be decreased when combined with Nefazodone.Approved, Investigational
EplerenoneThe serum concentration of Eplerenone can be increased when it is combined with Nefazodone.Approved
EquileninThe serum concentration of Equilenin can be increased when it is combined with Nefazodone.Experimental
EquilinThe serum concentration of Equilin can be increased when it is combined with Nefazodone.Approved
ErgocalciferolThe metabolism of Ergocalciferol can be decreased when combined with Nefazodone.Approved, Nutraceutical
Ergoloid mesylateThe metabolism of Ergoloid mesylate can be decreased when combined with Nefazodone.Approved
ErgonovineThe metabolism of Ergonovine can be decreased when combined with Nefazodone.Approved
ErgotamineThe metabolism of Ergotamine can be decreased when combined with Nefazodone.Approved
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Nefazodone.Approved, Investigational
ErythromycinThe metabolism of Erythromycin can be decreased when combined with Nefazodone.Approved, Vet Approved
EscitalopramThe metabolism of Escitalopram can be decreased when combined with Nefazodone.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Nefazodone can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsmololThe serum concentration of Esmolol can be increased when it is combined with Nefazodone.Approved
EsomeprazoleThe metabolism of Esomeprazole can be decreased when combined with Nefazodone.Approved, Investigational
EstazolamThe serum concentration of Estazolam can be increased when it is combined with Nefazodone.Approved, Illicit
EstradiolThe metabolism of Estradiol can be decreased when combined with Nefazodone.Approved, Investigational, Vet Approved
Estradiol valerate/DienogestThe metabolism of Estradiol valerate/Dienogest can be decreased when combined with Nefazodone.Approved
EstramustineThe metabolism of Estramustine can be decreased when combined with Nefazodone.Approved
EstriolThe serum concentration of Estriol can be decreased when it is combined with Nefazodone.Approved, Vet Approved
EstroneThe metabolism of Estrone can be decreased when combined with Nefazodone.Approved
Estrone sulfateThe metabolism of Estrone sulfate can be decreased when combined with Nefazodone.Approved
EszopicloneThe metabolism of Eszopiclone can be decreased when combined with Nefazodone.Approved
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Nefazodone.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Nefazodone.Approved, Illicit, Withdrawn
Ethinyl EstradiolThe metabolism of Ethinyl Estradiol can be decreased when combined with Nefazodone.Approved
EthosuximideThe metabolism of Ethosuximide can be decreased when combined with Nefazodone.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Nefazodone.Approved
Ethyl biscoumacetateNefazodone may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Nefazodone.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Nefazodone.Approved, Illicit
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Nefazodone.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Nefazodone.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Nefazodone.Withdrawn
EtizolamThe serum concentration of Etizolam can be increased when it is combined with Nefazodone.Approved
EtodolacNefazodone may increase the antiplatelet activities of Etodolac.Approved, Investigational, Vet Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Nefazodone.Approved
EtonogestrelThe metabolism of Etonogestrel can be decreased when combined with Nefazodone.Approved, Investigational
EtoperidoneNefazodone may increase the serotonergic activities of Etoperidone.Approved
EtoposideThe metabolism of Etoposide can be decreased when combined with Nefazodone.Approved
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Nefazodone.Approved, Investigational
EtorphineEtorphine may increase the serotonergic activities of Nefazodone.Illicit, Vet Approved
EtravirineThe metabolism of Etravirine can be decreased when combined with Nefazodone.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Nefazodone.Approved
ExemestaneThe metabolism of Exemestane can be decreased when combined with Nefazodone.Approved, Investigational
ExenatideNefazodone may increase the hypoglycemic activities of Exenatide.Approved, Investigational
EzetimibeThe serum concentration of Ezetimibe can be decreased when it is combined with Nefazodone.Approved
EzogabineThe risk or severity of adverse effects can be increased when Ezogabine is combined with Nefazodone.Approved
FamciclovirThe metabolism of Famciclovir can be decreased when combined with Nefazodone.Approved
FelbamateThe metabolism of Felbamate can be decreased when combined with Nefazodone.Approved
FelodipineThe metabolism of Felodipine can be decreased when combined with Nefazodone.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Nefazodone is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenfluramineNefazodone may increase the serotonergic activities of Fenfluramine.Illicit, Withdrawn
FenofibrateThe metabolism of Fenofibrate can be decreased when combined with Nefazodone.Approved
FentanylThe serum concentration of Fentanyl can be increased when it is combined with Nefazodone.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Nefazodone.Approved
FexofenadineThe serum concentration of Fexofenadine can be decreased when it is combined with Nefazodone.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be decreased when it is combined with Nefazodone.Approved
FinasterideThe metabolism of Finasteride can be decreased when combined with Nefazodone.Approved
FingolimodThe metabolism of Fingolimod can be decreased when combined with Nefazodone.Approved, Investigational
FlibanserinThe serum concentration of Flibanserin can be increased when it is combined with Nefazodone.Approved
fluasteroneThe serum concentration of fluasterone can be increased when it is combined with Nefazodone.Investigational
FluconazoleThe metabolism of Nefazodone can be decreased when combined with Fluconazole.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Nefazodone.Approved, Illicit
FludrocortisoneThe serum concentration of Fludrocortisone can be increased when it is combined with Nefazodone.Approved
FluindioneNefazodone may increase the anticoagulant activities of Fluindione.Investigational
FlumethasoneThe serum concentration of Flumethasone can be increased when it is combined with Nefazodone.Approved, Vet Approved
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Nefazodone.Approved
FlunisolideThe metabolism of Flunisolide can be decreased when combined with Nefazodone.Approved, Investigational
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Nefazodone.Approved, Illicit
Fluocinolone AcetonideThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Nefazodone.Approved, Investigational, Vet Approved
FluocinonideThe serum concentration of Fluocinonide can be increased when it is combined with Nefazodone.Approved, Investigational
FluocortoloneThe serum concentration of Fluocortolone can be increased when it is combined with Nefazodone.Approved, Withdrawn
FluorometholoneThe metabolism of Fluorometholone can be decreased when combined with Nefazodone.Approved
FluoxetineThe metabolism of Fluoxetine can be decreased when combined with Nefazodone.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Nefazodone is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Nefazodone is combined with Fluphenazine.Approved
FluprednideneThe serum concentration of Fluprednidene can be increased when it is combined with Nefazodone.Approved, Withdrawn
FluprednisoloneThe serum concentration of Fluprednisolone can be increased when it is combined with Nefazodone.Approved
FlurandrenolideThe serum concentration of Flurandrenolide can be increased when it is combined with Nefazodone.Approved
FlurazepamThe metabolism of Flurazepam can be decreased when combined with Nefazodone.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Fluspirilene.Approved
FlutamideThe metabolism of Flutamide can be decreased when combined with Nefazodone.Approved
Fluticasone furoateThe metabolism of Fluticasone furoate can be decreased when combined with Nefazodone.Approved
Fluticasone PropionateThe serum concentration of Fluticasone Propionate can be increased when it is combined with Nefazodone.Approved
Fluticasone PropionateThe metabolism of Fluticasone Propionate can be decreased when combined with Nefazodone.Approved
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Nefazodone.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Nefazodone.Approved, Investigational
FormestaneThe serum concentration of Formestane can be increased when it is combined with Nefazodone.Approved, Investigational, Withdrawn
FosamprenavirThe serum concentration of Nefazodone can be increased when it is combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Nefazodone can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe serum concentration of Nefazodone can be increased when it is combined with Fosinopril.Approved
FosphenytoinThe metabolism of Nefazodone can be increased when combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Nefazodone.Approved, Illicit
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Nefazodone.Approved, Investigational
FulvestrantThe metabolism of Fulvestrant can be decreased when combined with Nefazodone.Approved, Investigational
FurazolidoneFurazolidone may increase the serotonergic activities of Nefazodone.Approved, Vet Approved
Fusidic AcidThe serum concentration of Nefazodone can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Nefazodone.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when gabapentin enacarbil is combined with Nefazodone.Approved
GabexateThe serum concentration of Nefazodone can be increased when it is combined with Gabexate.Investigational
GalantamineThe metabolism of Galantamine can be decreased when combined with Nefazodone.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Nefazodone.Approved, Illicit
GefitinibThe metabolism of Gefitinib can be decreased when combined with Nefazodone.Approved, Investigational
GeldanamycinThe serum concentration of Nefazodone can be increased when it is combined with Geldanamycin.Experimental
GemcitabineThe serum concentration of Gemcitabine can be decreased when it is combined with Nefazodone.Approved
GemfibrozilThe metabolism of Gemfibrozil can be decreased when combined with Nefazodone.Approved
GepironeThe risk or severity of adverse effects can be increased when Gepirone is combined with Nefazodone.Investigational
GliclazideNefazodone may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideNefazodone may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideThe metabolism of Glipizide can be decreased when combined with Nefazodone.Approved
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Nefazodone.Approved, Illicit
GlyburideThe metabolism of Glyburide can be decreased when combined with Nefazodone.Approved
GM6001The serum concentration of Nefazodone can be increased when it is combined with GM6001.Experimental
GranisetronThe metabolism of Granisetron can be decreased when combined with Nefazodone.Approved, Investigational
GrazoprevirThe serum concentration of Grazoprevir can be decreased when it is combined with Nefazodone.Approved
GrepafloxacinThe metabolism of Grepafloxacin can be decreased when combined with Nefazodone.Withdrawn
GuanfacineThe serum concentration of Guanfacine can be increased when it is combined with Nefazodone.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Nefazodone.Approved, Illicit, Withdrawn
HalofantrineThe serum concentration of Halofantrine can be increased when it is combined with Nefazodone.Approved
HaloperidolThe metabolism of Haloperidol can be decreased when combined with Nefazodone.Approved
HalothaneThe metabolism of Halothane can be decreased when combined with Nefazodone.Approved, Vet Approved
HE3286The serum concentration of HE3286 can be increased when it is combined with Nefazodone.Investigational
HeroinHeroin may increase the serotonergic activities of Nefazodone.Approved, Illicit
HexobarbitalThe metabolism of Hexobarbital can be decreased when combined with Nefazodone.Approved
HirulogThe serum concentration of Nefazodone can be increased when it is combined with Hirulog.Experimental
Histamine PhosphateThe metabolism of Histamine Phosphate can be decreased when combined with Nefazodone.Approved
HydracarbazineHydracarbazine may increase the serotonergic activities of Nefazodone.Approved
HydrochlorothiazideNefazodone may increase the hyponatremic activities of Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneThe serum concentration of Hydrocodone can be increased when it is combined with Nefazodone.Approved, Illicit
HydrocortisoneThe metabolism of Hydrocortisone can be decreased when combined with Nefazodone.Approved, Vet Approved
HydroflumethiazideNefazodone may increase the hyponatremic activities of Hydroflumethiazide.Approved
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Nefazodone.Approved, Illicit
Hydroxyprogesterone caproateThe metabolism of Hydroxyprogesterone caproate can be decreased when combined with Nefazodone.Approved
HydroxyzineThe risk or severity of adverse effects can be increased when Hydroxyzine is combined with Nefazodone.Approved
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Nefazodone.Approved
IbuprofenThe serum concentration of Ibuprofen can be decreased when it is combined with Nefazodone.Approved
IdelalisibThe serum concentration of Nefazodone can be increased when it is combined with Idelalisib.Approved
idraparinuxThe serum concentration of Nefazodone can be increased when it is combined with idraparinux.Investigational
IfosfamideThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Nefazodone resulting in a loss in efficacy.Approved
IloperidoneThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Nefazodone.Approved
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Nefazodone.Approved
ImidafenacinThe serum concentration of Imidafenacin can be increased when it is combined with Nefazodone.Approved
ImidaprilThe serum concentration of Nefazodone can be increased when it is combined with Imidapril.Investigational
ImipramineThe metabolism of Imipramine can be decreased when combined with Nefazodone.Approved
ImiquimodThe metabolism of Imiquimod can be decreased when combined with Nefazodone.Approved, Investigational
IndacaterolThe metabolism of Indacaterol can be decreased when combined with Nefazodone.Approved
IndalpineNefazodone may increase the serotonergic activities of Indalpine.Investigational, Withdrawn
IndapamideThe metabolism of Indapamide can be decreased when combined with Nefazodone.Approved
IndenololThe serum concentration of Indenolol can be increased when it is combined with Nefazodone.Withdrawn
IndinavirThe serum concentration of Nefazodone can be increased when it is combined with Indinavir.Approved
IndomethacinThe serum concentration of Indomethacin can be decreased when it is combined with Nefazodone.Approved, Investigational
Insulin AspartNefazodone may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirNefazodone may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineNefazodone may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineNefazodone may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanNefazodone may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproNefazodone may increase the hypoglycemic activities of Insulin Lispro.Approved
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Nefazodone.Approved
Ioflupane I-123Nefazodone may decrease effectiveness of Ioflupane I-123 as a diagnostic agent.Approved
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Nefazodone.Approved
IproclozideIproclozide may increase the serotonergic activities of Nefazodone.Withdrawn
IproniazidIproniazid may increase the serotonergic activities of Nefazodone.Withdrawn
IrinotecanThe serum concentration of the active metabolites of Irinotecan can be increased when Irinotecan is used in combination with Nefazodone.Approved, Investigational
IsavuconazoniumThe serum concentration of the active metabolites of Isavuconazonium can be increased when Isavuconazonium is used in combination with Nefazodone.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the serotonergic activities of Nefazodone.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Nefazodone.Approved, Vet Approved
IsoflurophateThe serum concentration of Nefazodone can be increased when it is combined with Isoflurophate.Approved, Withdrawn
IsoniazidThe metabolism of Nefazodone can be decreased when combined with Isoniazid.Approved
Isosorbide DinitrateThe metabolism of Isosorbide Dinitrate can be decreased when combined with Nefazodone.Approved
Isosorbide MononitrateThe metabolism of Isosorbide Mononitrate can be decreased when combined with Nefazodone.Approved
IsradipineThe metabolism of Isradipine can be decreased when combined with Nefazodone.Approved
IstaroximeThe serum concentration of Istaroxime can be increased when it is combined with Nefazodone.Investigational
ItraconazoleThe metabolism of Itraconazole can be decreased when combined with Nefazodone.Approved, Investigational
IvabradineThe serum concentration of Ivabradine can be increased when it is combined with Nefazodone.Approved
IvacaftorThe serum concentration of Ivacaftor can be increased when it is combined with Nefazodone.Approved
IvermectinThe metabolism of Ivermectin can be decreased when combined with Nefazodone.Approved, Vet Approved
IxabepiloneThe serum concentration of Ixabepilone can be increased when it is combined with Nefazodone.Approved, Investigational
IxazomibThe serum concentration of Nefazodone can be increased when it is combined with Ixazomib.Approved
KetamineThe metabolism of Ketamine can be decreased when combined with Nefazodone.Approved, Vet Approved
KetazolamThe metabolism of Ketazolam can be decreased when combined with Nefazodone.Approved
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Nefazodone.Approved
KetoconazoleThe metabolism of Nefazodone can be decreased when combined with Ketoconazole.Approved, Investigational
L-TryptophanL-Tryptophan may increase the serotonergic activities of Nefazodone.Approved, Nutraceutical
LabetalolThe serum concentration of Labetalol can be increased when it is combined with Nefazodone.Approved
LacosamideThe serum concentration of Lacosamide can be increased when it is combined with Nefazodone.Approved
LamivudineThe serum concentration of Lamivudine can be decreased when it is combined with Nefazodone.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be decreased when it is combined with Nefazodone.Approved, Investigational
LanreotideNefazodone may increase the hypoglycemic activities of Lanreotide.Approved
LansoprazoleThe metabolism of Lansoprazole can be decreased when combined with Nefazodone.Approved, Investigational
LapatinibThe serum concentration of Lapatinib can be increased when it is combined with Nefazodone.Approved, Investigational
LaquinimodThe metabolism of Laquinimod can be decreased when combined with Nefazodone.Investigational
LedipasvirThe serum concentration of Ledipasvir can be decreased when it is combined with Nefazodone.Approved
LenalidomideThe serum concentration of Lenalidomide can be decreased when it is combined with Nefazodone.Approved
LenvatinibThe metabolism of Lenvatinib can be decreased when combined with Nefazodone.Approved
LepirudinThe serum concentration of Nefazodone can be increased when it is combined with Lepirudin.Approved
LercanidipineThe serum concentration of Lercanidipine can be increased when it is combined with Nefazodone.Approved, Investigational
LetrozoleThe metabolism of Letrozole can be decreased when combined with Nefazodone.Approved, Investigational
LevetiracetamThe serum concentration of Levetiracetam can be decreased when it is combined with Nefazodone.Approved, Investigational
LevobunololThe serum concentration of Levobunolol can be increased when it is combined with Nefazodone.Approved
LevobupivacaineThe serum concentration of Levobupivacaine can be increased when it is combined with Nefazodone.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Levocabastine is combined with Nefazodone.Approved
LevocetirizineThe metabolism of Levocetirizine can be decreased when combined with Nefazodone.Approved
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Nefazodone.Approved
LevofloxacinThe serum concentration of Levofloxacin can be decreased when it is combined with Nefazodone.Approved, Investigational
Levomethadyl AcetateThe metabolism of Levomethadyl Acetate can be decreased when combined with Nefazodone.Approved
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Nefazodone.Approved
LevonorgestrelThe metabolism of Levonorgestrel can be decreased when combined with Nefazodone.Approved, Investigational
LevorphanolLevorphanol may increase the serotonergic activities of Nefazodone.Approved
LevothyroxineThe metabolism of Levothyroxine can be decreased when combined with Nefazodone.Approved
LidocaineThe metabolism of Lidocaine can be decreased when combined with Nefazodone.Approved, Vet Approved
LinagliptinThe serum concentration of Nefazodone can be increased when it is combined with Linagliptin.Approved
LinezolidLinezolid may increase the serotonergic activities of Nefazodone.Approved, Investigational
LiothyronineThe therapeutic efficacy of Liothyronine can be decreased when used in combination with Nefazodone.Approved, Vet Approved
LiotrixThe therapeutic efficacy of Liotrix can be decreased when used in combination with Nefazodone.Approved
LiraglutideNefazodone may increase the hypoglycemic activities of Liraglutide.Approved
LisinoprilThe serum concentration of Nefazodone can be increased when it is combined with Lisinopril.Approved, Investigational
LisurideThe metabolism of Lisuride can be decreased when combined with Nefazodone.Approved
LithiumLithium may increase the serotonergic activities of Nefazodone.Approved
LofentanilLofentanil may increase the serotonergic activities of Nefazodone.Illicit
LomitapideThe serum concentration of Lomitapide can be increased when it is combined with Nefazodone.Approved
LoperamideThe metabolism of Loperamide can be decreased when combined with Nefazodone.Approved
LopinavirThe serum concentration of Nefazodone can be increased when it is combined with Lopinavir.Approved
LoratadineThe metabolism of Loratadine can be decreased when combined with Nefazodone.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Nefazodone.Approved
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Nefazodone.Approved
LosartanThe metabolism of Losartan can be decreased when combined with Nefazodone.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Nefazodone.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Nefazodone is combined with Loxapine.Approved
Lu AA21004Nefazodone may increase the serotonergic activities of Lu AA21004.Investigational
LuliconazoleThe serum concentration of Nefazodone can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Nefazodone can be increased when combined with Lumacaftor.Approved
LumefantrineThe serum concentration of Lumefantrine can be increased when it is combined with Nefazodone.Approved
LumiracoxibNefazodone may increase the antiplatelet activities of Lumiracoxib.Approved, Investigational
LurasidoneThe serum concentration of Lurasidone can be increased when it is combined with Nefazodone.Approved
MacitentanThe serum concentration of Macitentan can be increased when it is combined with Nefazodone.Approved
Magnesium SulfateThe risk or severity of adverse effects can be increased when Magnesium Sulfate is combined with Nefazodone.Approved, Vet Approved
MannitolThe serum concentration of Mannitol can be decreased when it is combined with Nefazodone.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Nefazodone.Approved
MaravirocThe serum concentration of Maraviroc can be increased when it is combined with Nefazodone.Approved, Investigational
ME-609The serum concentration of ME-609 can be increased when it is combined with Nefazodone.Investigational
MebanazineMebanazine may increase the serotonergic activities of Nefazodone.Withdrawn
MebendazoleThe metabolism of Mebendazole can be decreased when combined with Nefazodone.Approved, Vet Approved
MecaserminNefazodone may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Nefazodone.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Nefazodone.Vet Approved
Medroxyprogesterone acetateThe serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Nefazodone.Approved, Investigational
MedrysoneThe serum concentration of Medrysone can be increased when it is combined with Nefazodone.Approved
MefloquineThe metabolism of Mefloquine can be decreased when combined with Nefazodone.Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Nefazodone.Approved, Nutraceutical, Vet Approved
MelengestrolThe serum concentration of Melengestrol can be increased when it is combined with Nefazodone.Vet Approved
MeloxicamThe metabolism of Meloxicam can be decreased when combined with Nefazodone.Approved, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Melperone.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Nefazodone.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Nefazodone.Approved, Illicit
MesoridazineThe risk or severity of adverse effects can be increased when Nefazodone is combined with Mesoridazine.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Nefazodone.Approved
MetforminNefazodone may increase the hypoglycemic activities of Metformin.Approved
MethadoneThe metabolism of Methadone can be decreased when combined with Nefazodone.Approved
Methadyl AcetateMethadyl Acetate may increase the serotonergic activities of Nefazodone.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Nefazodone.Withdrawn
MethaqualoneThe metabolism of Methaqualone can be decreased when combined with Nefazodone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Nefazodone.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Nefazodone.Approved
MethotrexateThe serum concentration of Methotrexate can be decreased when it is combined with Nefazodone.Approved
MethotrimeprazineThe metabolism of Nefazodone can be decreased when combined with Methotrimeprazine.Approved
MethoxsalenThe metabolism of Methoxsalen can be decreased when combined with Nefazodone.Approved
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Nefazodone.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Nefazodone.Approved
MethyclothiazideNefazodone may increase the hyponatremic activities of Methyclothiazide.Approved
Methylene blueNefazodone may increase the serotonergic activities of Methylene blue.Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Nefazodone.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Nefazodone.Approved, Vet Approved
MethyltestosteroneThe metabolism of Methyltestosterone can be decreased when combined with Nefazodone.Approved
MetipranololThe serum concentration of Metipranolol can be increased when it is combined with Nefazodone.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Nefazodone.Approved, Investigational
MetolazoneNefazodone may increase the hyponatremic activities of Metolazone.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Nefazodone.Approved, Investigational
MetronidazoleThe metabolism of Metronidazole can be decreased when combined with Nefazodone.Approved
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Nefazodone.Approved
MexiletineThe metabolism of Mexiletine can be decreased when combined with Nefazodone.Approved
MianserinThe metabolism of Mianserin can be decreased when combined with Nefazodone.Approved
MibefradilThe metabolism of Mibefradil can be decreased when combined with Nefazodone.Withdrawn
MiconazoleThe metabolism of Miconazole can be decreased when combined with Nefazodone.Approved, Investigational, Vet Approved
MidazolamThe metabolism of Midazolam can be decreased when combined with Nefazodone.Approved, Illicit
MifepristoneThe serum concentration of Nefazodone can be increased when it is combined with Mifepristone.Approved, Investigational
MiglitolNefazodone may increase the hypoglycemic activities of Miglitol.Approved
MilnacipranThe risk or severity of adverse effects can be increased when Nefazodone is combined with Milnacipran.Approved
MinaprineMinaprine may increase the serotonergic activities of Nefazodone.Approved
MirabegronThe metabolism of Mirabegron can be decreased when combined with Nefazodone.Approved
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Nefazodone.Approved
MitotaneThe serum concentration of Nefazodone can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be decreased when it is combined with Nefazodone.Approved, Investigational
MoclobemideMoclobemide may increase the serotonergic activities of Nefazodone.Approved
ModafinilThe metabolism of Modafinil can be decreased when combined with Nefazodone.Approved, Investigational
MoexiprilThe serum concentration of Nefazodone can be increased when it is combined with Moexipril.Approved
MolindoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Molindone.Approved
MometasoneThe serum concentration of Mometasone can be increased when it is combined with Nefazodone.Approved, Vet Approved
MontelukastThe metabolism of Montelukast can be decreased when combined with Nefazodone.Approved
MorphineThe metabolism of Morphine can be decreased when combined with Nefazodone.Approved, Investigational
Mycophenolate mofetilThe metabolism of Mycophenolate mofetil can be decreased when combined with Nefazodone.Approved, Investigational
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-ProlineThe serum concentration of Nefazodone can be increased when it is combined with N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline.Experimental
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Nefazodone.Approved, Investigational
NabumetoneNefazodone may increase the antiplatelet activities of Nabumetone.Approved
NadololThe serum concentration of Nadolol can be decreased when it is combined with Nefazodone.Approved
NafamostatThe serum concentration of Nefazodone can be increased when it is combined with Nafamostat.Investigational
NafcillinThe serum concentration of Nefazodone can be decreased when it is combined with Nafcillin.Approved
NalbuphineNalbuphine may increase the serotonergic activities of Nefazodone.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Nefazodone.Approved
NaloxoneThe metabolism of Naloxone can be decreased when combined with Nefazodone.Approved, Vet Approved
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Nefazodone.Approved, Investigational
NateglinideThe metabolism of Nateglinide can be decreased when combined with Nefazodone.Approved, Investigational
NCX 1022The serum concentration of NCX 1022 can be increased when it is combined with Nefazodone.Investigational
NCX 4016The serum concentration of Nefazodone can be increased when it is combined with NCX 4016.Investigational
NelfinavirThe serum concentration of Nefazodone can be increased when it is combined with Nelfinavir.Approved
NetupitantThe serum concentration of Nefazodone can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Nefazodone can be increased when combined with Nevirapine.Approved
NialamideNialamide may increase the serotonergic activities of Nefazodone.Withdrawn
NicardipineThe metabolism of Nicardipine can be decreased when combined with Nefazodone.Approved
NicotineThe metabolism of Nicotine can be decreased when combined with Nefazodone.Approved
NifedipineThe metabolism of Nifedipine can be decreased when combined with Nefazodone.Approved
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Nefazodone.Approved, Investigational
NilvadipineThe metabolism of Nilvadipine can be decreased when combined with Nefazodone.Approved
NimodipineThe serum concentration of Nimodipine can be increased when it is combined with Nefazodone.Approved
NintedanibThe serum concentration of Nintedanib can be decreased when it is combined with Nefazodone.Approved
NisoldipineThe serum concentration of Nisoldipine can be increased when it is combined with Nefazodone.Approved
NitrazepamThe metabolism of Nitrazepam can be decreased when combined with Nefazodone.Approved
NitrendipineThe metabolism of Nitrendipine can be decreased when combined with Nefazodone.Approved
NitroaspirinThe serum concentration of Nefazodone can be increased when it is combined with Nitroaspirin.Investigational
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Nefazodone.Approved, Vet Approved
NizatidineThe serum concentration of Nizatidine can be decreased when it is combined with Nefazodone.Approved
NorethisteroneThe metabolism of Norethisterone can be decreased when combined with Nefazodone.Approved
NorgestrelThe metabolism of Norgestrel can be decreased when combined with Nefazodone.Approved
NormethadoneNormethadone may increase the serotonergic activities of Nefazodone.Approved, Illicit
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Nefazodone.Approved
OctamoxinOctamoxin may increase the serotonergic activities of Nefazodone.Withdrawn
OctreotideNefazodone may increase the hypoglycemic activities of Octreotide.Approved, Investigational
OlanzapineNefazodone may increase the serotonergic activities of Olanzapine.Approved, Investigational
OlaparibThe serum concentration of Olaparib can be increased when it is combined with Nefazodone.Approved
Oleoyl estroneThe serum concentration of Oleoyl estrone can be increased when it is combined with Nefazodone.Investigational
OlopatadineThe metabolism of Olopatadine can be decreased when combined with Nefazodone.Approved
OmapatrilatThe serum concentration of Nefazodone can be increased when it is combined with Omapatrilat.Investigational
OmbitasvirThe serum concentration of Ombitasvir can be decreased when it is combined with Nefazodone.Approved
OmeprazoleThe metabolism of Omeprazole can be decreased when combined with Nefazodone.Approved, Investigational, Vet Approved
OndansetronThe metabolism of Ondansetron can be decreased when combined with Nefazodone.Approved
OpiumOpium may increase the serotonergic activities of Nefazodone.Approved, Illicit
OrphenadrineThe metabolism of Orphenadrine can be decreased when combined with Nefazodone.Approved
OsanetantThe risk or severity of adverse effects can be increased when Nefazodone is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Osimertinib can be increased when it is combined with Nefazodone.Approved
OspemifeneThe serum concentration of Ospemifene can be increased when it is combined with Nefazodone.Approved
OtamixabanThe serum concentration of Nefazodone can be increased when it is combined with Otamixaban.Investigational
OxazepamThe metabolism of Oxazepam can be decreased when combined with Nefazodone.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Oxetacaine is combined with Nefazodone.Investigational
OxprenololThe serum concentration of Oxprenolol can be increased when it is combined with Nefazodone.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Nefazodone.Approved
OxybutyninThe serum concentration of Oxybutynin can be increased when it is combined with Nefazodone.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Nefazodone.Approved, Investigational, Vet Approved
PaclitaxelThe metabolism of Paclitaxel can be decreased when combined with Nefazodone.Approved, Vet Approved
PalbociclibThe serum concentration of Palbociclib can be increased when it is combined with Nefazodone.Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Paliperidone.Approved
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Nefazodone.Approved, Investigational
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Nefazodone.Approved, Investigational
PantoprazoleThe metabolism of Pantoprazole can be decreased when combined with Nefazodone.Approved
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Nefazodone.Approved
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Nefazodone.Approved
ParamethasoneThe metabolism of Paramethasone can be decreased when combined with Nefazodone.Approved
ParecoxibThe serum concentration of Parecoxib can be increased when it is combined with Nefazodone.Approved
PargylinePargyline may increase the serotonergic activities of Nefazodone.Approved
ParicalcitolThe serum concentration of Paricalcitol can be increased when it is combined with Nefazodone.Approved, Investigational
ParitaprevirThe metabolism of Paritaprevir can be decreased when combined with Nefazodone.Approved
ParoxetineThe metabolism of Nefazodone can be decreased when combined with Paroxetine.Approved, Investigational
PasireotideNefazodone may increase the hypoglycemic activities of Pasireotide.Approved
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Nefazodone.Approved
Peginterferon alfa-2bThe serum concentration of Nefazodone can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenbutololThe serum concentration of Penbutolol can be increased when it is combined with Nefazodone.Approved, Investigational
PentamidineThe metabolism of Pentamidine can be decreased when combined with Nefazodone.Approved
PentazocinePentazocine may increase the serotonergic activities of Nefazodone.Approved, Vet Approved
PentobarbitalThe metabolism of Nefazodone can be increased when combined with Pentobarbital.Approved, Vet Approved
PerampanelThe metabolism of Perampanel can be decreased when combined with Nefazodone.Approved
PerazineThe risk or severity of adverse effects can be increased when Nefazodone is combined with Perazine.Investigational
PergolideThe metabolism of Pergolide can be decreased when combined with Nefazodone.Approved, Vet Approved, Withdrawn
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Nefazodone.Approved
PerindoprilThe serum concentration of Nefazodone can be increased when it is combined with Perindopril.Approved
PermethrinThe metabolism of Permethrin can be decreased when combined with Nefazodone.Approved, Investigational
PerospironeThe risk or severity of adverse effects can be increased when Nefazodone is combined with Perospirone.Approved
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Nefazodone.Approved
PethidineThe metabolism of Pethidine can be decreased when combined with Nefazodone.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Nefazodone.Withdrawn
PhenelzinePhenelzine may increase the serotonergic activities of Nefazodone.Approved
PhenindioneNefazodone may increase the anticoagulant activities of Phenindione.Approved
PheniprazinePheniprazine may increase the serotonergic activities of Nefazodone.Withdrawn
PhenobarbitalThe metabolism of Nefazodone can be increased when combined with Phenobarbital.Approved
PhenoxybenzamineThe metabolism of Phenoxybenzamine can be decreased when combined with Nefazodone.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Nefazodone.Approved
PhenoxypropazinePhenoxypropazine may increase the serotonergic activities of Nefazodone.Withdrawn
PhenprocoumonThe metabolism of Phenprocoumon can be decreased when combined with Nefazodone.Approved
PhenytoinThe metabolism of Nefazodone can be increased when combined with Phenytoin.Approved, Vet Approved
PhosphoramidonThe serum concentration of Nefazodone can be increased when it is combined with Phosphoramidon.Experimental
PilocarpineThe metabolism of Pilocarpine can be decreased when combined with Nefazodone.Approved
PimecrolimusThe metabolism of Pimecrolimus can be decreased when combined with Nefazodone.Approved, Investigational
PimozideThe serum concentration of Pimozide can be increased when it is combined with Nefazodone.Approved
PinacidilThe metabolism of Pinacidil can be decreased when combined with Nefazodone.Withdrawn
PindololThe serum concentration of Pindolol can be increased when it is combined with Nefazodone.Approved
PioglitazoneThe metabolism of Pioglitazone can be decreased when combined with Nefazodone.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Pipamperone.Approved
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Nefazodone.Approved
PiritramidePiritramide may increase the serotonergic activities of Nefazodone.Investigational
PirlindolePirlindole may increase the serotonergic activities of Nefazodone.Approved
PitavastatinThe serum concentration of Pitavastatin can be decreased when it is combined with Nefazodone.Approved
PivhydrazinePivhydrazine may increase the serotonergic activities of Nefazodone.Withdrawn
PizotifenThe risk or severity of adverse effects can be increased when Pizotifen is combined with Nefazodone.Approved
PodofiloxThe metabolism of Podofilox can be decreased when combined with Nefazodone.Approved
PolythiazideNefazodone may increase the hyponatremic activities of Polythiazide.Approved
PomalidomideThe metabolism of Pomalidomide can be decreased when combined with Nefazodone.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Nefazodone.Approved
PosaconazoleThe metabolism of Posaconazole can be decreased when combined with Nefazodone.Approved, Investigational, Vet Approved
PractololThe serum concentration of Practolol can be increased when it is combined with Nefazodone.Approved
PramlintideNefazodone may increase the hypoglycemic activities of Pramlintide.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Nefazodone.Approved
PranlukastThe serum concentration of Pranlukast can be increased when it is combined with Nefazodone.Approved
PrasteroneThe metabolism of Prasterone can be decreased when combined with Nefazodone.Approved, Nutraceutical
PrasugrelThe serum concentration of the active metabolites of Prasugrel can be reduced when Prasugrel is used in combination with Nefazodone resulting in a loss in efficacy.Approved
PravastatinThe metabolism of Pravastatin can be decreased when combined with Nefazodone.Approved
PrazepamThe metabolism of Prazepam can be decreased when combined with Nefazodone.Approved, Illicit
PraziquantelThe metabolism of Praziquantel can be decreased when combined with Nefazodone.Approved, Vet Approved
PrazosinThe serum concentration of Prazosin can be decreased when it is combined with Nefazodone.Approved
PrednicarbateThe serum concentration of Prednicarbate can be increased when it is combined with Nefazodone.Approved
PrednisoloneThe metabolism of Prednisolone can be decreased when combined with Nefazodone.Approved, Vet Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Nefazodone.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Nefazodone.Approved, Vet Approved
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Nefazodone.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Pregnanolone is combined with Nefazodone.Investigational
PregnenoloneThe serum concentration of Pregnenolone can be increased when it is combined with Nefazodone.Experimental
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Nefazodone.Approved
PrimaquineThe metabolism of Primaquine can be decreased when combined with Nefazodone.Approved
PrimidoneThe metabolism of Nefazodone can be increased when combined with Primidone.Approved, Vet Approved
PrinomastatThe serum concentration of Nefazodone can be increased when it is combined with Prinomastat.Investigational
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Nefazodone.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Nefazodone is combined with Procarbazine.Approved
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Nefazodone.Approved, Vet Approved
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Nefazodone.Approved, Vet Approved
ProguanilThe metabolism of Proguanil can be decreased when combined with Nefazodone.Approved
PromazineThe metabolism of Promazine can be decreased when combined with Nefazodone.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Nefazodone.Approved
PropafenoneThe serum concentration of Propafenone can be increased when it is combined with Nefazodone.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Nefazodone.Approved, Vet Approved
PropericiazineThe risk or severity of adverse effects can be increased when Nefazodone is combined with Propericiazine.Approved
PropofolThe metabolism of Propofol can be decreased when combined with Nefazodone.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Nefazodone.Approved
PropranololThe metabolism of Propranolol can be decreased when combined with Nefazodone.Approved, Investigational
ProthipendylThe risk or severity of adverse effects can be increased when Nefazodone is combined with Prothipendyl.Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Nefazodone.Approved
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Nefazodone.Investigational
PyrazinamideThe metabolism of Pyrazinamide can be decreased when combined with Nefazodone.Approved
QuazepamThe metabolism of Quazepam can be decreased when combined with Nefazodone.Approved, Illicit
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Nefazodone.Approved
QuinacrineThe metabolism of Quinacrine can be decreased when combined with Nefazodone.Approved
QuinaprilThe serum concentration of Nefazodone can be increased when it is combined with Quinapril.Approved, Investigational
QuinethazoneNefazodone may increase the hyponatremic activities of Quinethazone.Approved
QuinidineThe metabolism of Quinidine can be decreased when combined with Nefazodone.Approved
QuinineThe metabolism of Quinine can be decreased when combined with Nefazodone.Approved
RabeprazoleThe metabolism of Rabeprazole can be decreased when combined with Nefazodone.Approved, Investigational
RacecadotrilThe serum concentration of Nefazodone can be increased when it is combined with Racecadotril.Investigational
RacloprideThe risk or severity of adverse effects can be increased when Nefazodone is combined with Raclopride.Investigational
RaloxifeneThe metabolism of Raloxifene can be decreased when combined with Nefazodone.Approved, Investigational
RamelteonThe serum concentration of Ramelteon can be increased when it is combined with Nefazodone.Approved, Investigational
RamiprilThe serum concentration of Nefazodone can be increased when it is combined with Ramipril.Approved
RanitidineThe serum concentration of Ranitidine can be decreased when it is combined with Nefazodone.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Nefazodone.Approved, Investigational
RasagilineRasagiline may increase the serotonergic activities of Nefazodone.Approved
ReboxetineThe metabolism of Reboxetine can be decreased when combined with Nefazodone.Approved, Investigational
RegorafenibThe serum concentration of Regorafenib can be increased when it is combined with Nefazodone.Approved
RemifentanilRemifentanil may increase the serotonergic activities of Nefazodone.Approved
RemikirenThe serum concentration of Nefazodone can be increased when it is combined with Remikiren.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Nefazodone is combined with Remoxipride.Approved, Withdrawn
RepaglinideThe serum concentration of Repaglinide can be increased when it is combined with Nefazodone.Approved, Investigational
ReserpineThe serum concentration of Reserpine can be decreased when it is combined with Nefazodone.Approved
RetapamulinThe serum concentration of Retapamulin can be increased when it is combined with Nefazodone.Approved
RifabutinThe metabolism of Nefazodone can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Nefazodone can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Nefazodone can be increased when combined with Rifapentine.Approved
RilpivirineThe serum concentration of Rilpivirine can be increased when it is combined with Nefazodone.Approved
RimexoloneThe serum concentration of Rimexolone can be increased when it is combined with Nefazodone.Approved
RimonabantThe metabolism of Rimonabant can be decreased when combined with Nefazodone.Approved, Investigational
RiociguatThe metabolism of Riociguat can be decreased when combined with Nefazodone.Approved
RisperidoneThe metabolism of Risperidone can be decreased when combined with Nefazodone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Nefazodone is combined with Ritanserin.Investigational
RitonavirThe serum concentration of Nefazodone can be increased when it is combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Nefazodone can be increased when it is combined with Rivaroxaban.Approved
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Nefazodone.Approved
RofecoxibThe metabolism of Rofecoxib can be decreased when combined with Nefazodone.Investigational, Withdrawn
RolapitantThe metabolism of Rolapitant can be decreased when combined with Nefazodone.Approved
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Nefazodone.Approved, Investigational
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Nefazodone.Vet Approved
RopiniroleThe metabolism of Ropinirole can be decreased when combined with Nefazodone.Approved, Investigational
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Nefazodone.Approved
RosiglitazoneNefazodone may increase the hypoglycemic activities of Rosiglitazone.Approved, Investigational
RosuvastatinThe metabolism of Rosuvastatin can be decreased when combined with Nefazodone.Approved
RotigotineThe metabolism of Rotigotine can be decreased when combined with Nefazodone.Approved
RoxithromycinThe metabolism of Roxithromycin can be decreased when combined with Nefazodone.Approved, Withdrawn
RuxolitinibThe serum concentration of Ruxolitinib can be increased when it is combined with Nefazodone.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Nefazodone.Experimental
SafrazineSafrazine may increase the serotonergic activities of Nefazodone.Withdrawn
Sage 547The risk or severity of adverse effects can be increased when Sage 547 is combined with Nefazodone.Investigational
Salicylic acidThe serum concentration of Salicylic acid can be decreased when it is combined with Nefazodone.Approved, Vet Approved
SalmeterolThe serum concentration of Salmeterol can be increased when it is combined with Nefazodone.Approved
SaquinavirThe serum concentration of Nefazodone can be increased when it is combined with Saquinavir.Approved, Investigational
SaxagliptinThe serum concentration of Nefazodone can be increased when it is combined with Saxagliptin.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Nefazodone.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Nefazodone.Approved, Vet Approved
SelegilineSelegiline may increase the serotonergic activities of Nefazodone.Approved, Investigational, Vet Approved
SelexipagThe metabolism of Selexipag can be decreased when combined with Nefazodone.Approved
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Nefazodone.Approved, Investigational
SertindoleThe metabolism of Sertindole can be decreased when combined with Nefazodone.Approved, Withdrawn
SertralineThe metabolism of Sertraline can be decreased when combined with Nefazodone.Approved
SevofluraneThe metabolism of Sevoflurane can be decreased when combined with Nefazodone.Approved, Vet Approved
SibutramineThe metabolism of Sibutramine can be decreased when combined with Nefazodone.Approved, Illicit, Investigational, Withdrawn
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Nefazodone.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Nefazodone.Approved
SiltuximabThe serum concentration of Nefazodone can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Nefazodone.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Nefazodone.Approved
SirolimusThe metabolism of Sirolimus can be decreased when combined with Nefazodone.Approved, Investigational
SitagliptinThe serum concentration of Nefazodone can be increased when it is combined with Sitagliptin.Approved, Investigational
Sodium oxybateThe risk or severity of adverse effects can be increased when Sodium oxybate is combined with Nefazodone.Approved
SofosbuvirThe serum concentration of Sofosbuvir can be decreased when it is combined with Nefazodone.Approved
SolifenacinThe metabolism of Solifenacin can be decreased when combined with Nefazodone.Approved
SonidegibThe serum concentration of Sonidegib can be increased when it is combined with Nefazodone.Approved, Investigational
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Nefazodone.Approved, Investigational
SotalolThe serum concentration of Sotalol can be increased when it is combined with Nefazodone.Approved
SparfloxacinThe serum concentration of Sparfloxacin can be decreased when it is combined with Nefazodone.Approved
SphingosineThe serum concentration of Sphingosine can be decreased when it is combined with Nefazodone.Experimental
SpiramycinThe metabolism of Spiramycin can be decreased when combined with Nefazodone.Approved
SpiraprilThe serum concentration of Nefazodone can be increased when it is combined with Spirapril.Approved
St. John's WortThe serum concentration of Nefazodone can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Nefazodone can be increased when it is combined with Stiripentol.Approved
SufentanilThe metabolism of Sufentanil can be decreased when combined with Nefazodone.Approved, Investigational
SulfadiazineThe metabolism of Sulfadiazine can be decreased when combined with Nefazodone.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Sulfamethoxazole can be decreased when combined with Nefazodone.Approved
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be decreased when combined with Nefazodone.Approved
SulfisoxazoleThe metabolism of Nefazodone can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Nefazodone is combined with Sulpiride.Approved
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Nefazodone.Approved, Investigational
SunitinibThe metabolism of Sunitinib can be decreased when combined with Nefazodone.Approved, Investigational
SuvorexantThe serum concentration of Suvorexant can be increased when it is combined with Nefazodone.Approved
Synthetic Conjugated Estrogens, AThe metabolism of Synthetic Conjugated Estrogens, A can be decreased when combined with Nefazodone.Approved
Synthetic Conjugated Estrogens, BThe metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Nefazodone.Approved
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Nefazodone.Approved, Investigational
TadalafilThe serum concentration of Tadalafil can be increased when it is combined with Nefazodone.Approved, Investigational
TamoxifenThe metabolism of Tamoxifen can be decreased when combined with Nefazodone.Approved
TamsulosinThe serum concentration of Tamsulosin can be increased when it is combined with Nefazodone.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Tandospirone is combined with Nefazodone.Investigational
TapentadolThe risk or severity of adverse effects can be increased when Nefazodone is combined with Tapentadol.Approved
TasimelteonThe serum concentration of Tasimelteon can be increased when it is combined with Nefazodone.Approved
TasosartanThe metabolism of Tasosartan can be decreased when combined with Nefazodone.Approved
Taurochenodeoxycholic acidThe metabolism of Taurochenodeoxycholic acid can be decreased when combined with Nefazodone.Experimental
Taurocholic AcidThe serum concentration of Taurocholic Acid can be decreased when it is combined with Nefazodone.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be decreased when it is combined with Nefazodone.Approved
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Nefazodone.Approved
TelaprevirThe serum concentration of Nefazodone can be increased when it is combined with Telaprevir.Approved
TelithromycinThe metabolism of Nefazodone can be decreased when combined with Telithromycin.Approved
TemazepamThe metabolism of Temazepam can be decreased when combined with Nefazodone.Approved
TemocaprilThe serum concentration of Nefazodone can be increased when it is combined with Temocapril.Experimental, Investigational
TemsirolimusThe metabolism of Temsirolimus can be decreased when combined with Nefazodone.Approved
TeniposideThe metabolism of Teniposide can be decreased when combined with Nefazodone.Approved
TerbinafineThe metabolism of Terbinafine can be decreased when combined with Nefazodone.Approved, Investigational, Vet Approved
TerfenadineThe serum concentration of Terfenadine can be increased when it is combined with Nefazodone.Withdrawn
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Nefazodone.Investigational
TestosteroneThe metabolism of Testosterone can be decreased when combined with Nefazodone.Approved, Investigational
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Nefazodone.Approved
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Nefazodone.Approved, Vet Approved
TetracyclineThe metabolism of Tetracycline can be decreased when combined with Nefazodone.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Nefazodone.Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Nefazodone.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Theophylline can be decreased when combined with Nefazodone.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Nefazodone.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Nefazodone.Approved, Vet Approved
ThioproperazineThe risk or severity of adverse effects can be increased when Nefazodone is combined with Thioproperazine.Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Nefazodone.Approved
ThiorphanThe serum concentration of Nefazodone can be increased when it is combined with Thiorphan.Experimental
ThiotepaThe metabolism of Thiotepa can be decreased when combined with Nefazodone.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Thiothixene.Approved
Thyroid, porcineThe therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Nefazodone.Approved
TiagabineThe metabolism of Tiagabine can be decreased when combined with Nefazodone.Approved
TiaprideThe risk or severity of adverse effects can be increased when Nefazodone is combined with Tiapride.Investigational
TicagrelorThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Nefazodone resulting in a loss in efficacy.Approved
TiclopidineThe metabolism of Ticlopidine can be decreased when combined with Nefazodone.Approved
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Nefazodone.Vet Approved
TimololThe serum concentration of Timolol can be decreased when it is combined with Nefazodone.Approved
TinidazoleThe metabolism of Tinidazole can be decreased when combined with Nefazodone.Approved, Investigational
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Nefazodone.Approved
TipranavirThe serum concentration of Nefazodone can be increased when it is combined with Tipranavir.Approved, Investigational
TixocortolThe serum concentration of Tixocortol can be increased when it is combined with Nefazodone.Approved
TizanidineThe serum concentration of Tizanidine can be increased when it is combined with Nefazodone.Approved
TocilizumabThe serum concentration of Nefazodone can be decreased when it is combined with Tocilizumab.Approved
TofacitinibThe serum concentration of Tofacitinib can be increased when it is combined with Nefazodone.Approved, Investigational
TolazamideNefazodone may increase the hypoglycemic activities of Tolazamide.Approved
TolbutamideNefazodone may increase the hypoglycemic activities of Tolbutamide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Nefazodone.Approved, Withdrawn
ToloxatoneToloxatone may increase the serotonergic activities of Nefazodone.Approved
TolterodineThe serum concentration of Tolterodine can be increased when it is combined with Nefazodone.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Nefazodone.Approved
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Nefazodone.Approved
TopotecanThe serum concentration of Topotecan can be decreased when it is combined with Nefazodone.Approved, Investigational
ToremifeneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Toremifene.Approved, Investigational
TrabectedinThe serum concentration of Trabectedin can be increased when it is combined with Nefazodone.Approved, Investigational
TramadolNefazodone may increase the neuroexcitatory activities of Tramadol.Approved, Investigational
TrandolaprilThe serum concentration of Nefazodone can be increased when it is combined with Trandolapril.Approved
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the serotonergic activities of Nefazodone.Experimental
TranylcypromineTranylcypromine may increase the serotonergic activities of Nefazodone.Approved
Trastuzumab emtansineThe serum concentration of the active metabolites of Trastuzumab emtansine can be increased when Trastuzumab emtansine is used in combination with Nefazodone.Approved
TrazodoneThe metabolism of Trazodone can be decreased when combined with Nefazodone.Approved, Investigational
TretinoinThe metabolism of Tretinoin can be decreased when combined with Nefazodone.Approved, Investigational, Nutraceutical
TriamcinoloneThe metabolism of Triamcinolone can be decreased when combined with Nefazodone.Approved, Vet Approved
TriazolamThe metabolism of Triazolam can be decreased when combined with Nefazodone.Approved
TrichlormethiazideNefazodone may increase the hyponatremic activities of Trichlormethiazide.Approved, Vet Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Nefazodone is combined with Trifluoperazine.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Nefazodone is combined with Triflupromazine.Approved, Vet Approved
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Nefazodone.Approved
TrimethoprimThe metabolism of Trimethoprim can be decreased when combined with Nefazodone.Approved, Vet Approved
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Nefazodone.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Nefazodone.Approved
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Nefazodone.Withdrawn
TroleandomycinThe metabolism of Troleandomycin can be decreased when combined with Nefazodone.Approved
TropisetronTropisetron may increase the serotonergic activities of Nefazodone.Investigational
UbenimexThe serum concentration of Nefazodone can be increased when it is combined with Ubenimex.Experimental
Uc1010The risk or severity of adverse effects can be increased when Uc1010 is combined with Nefazodone.Investigational
UdenafilThe metabolism of Udenafil can be decreased when combined with Nefazodone.Approved, Investigational
UlinastatinThe serum concentration of Nefazodone can be increased when it is combined with Ulinastatin.Investigational
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Nefazodone.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be decreased when it is combined with Nefazodone.Approved
ValdecoxibThe metabolism of Valdecoxib can be decreased when combined with Nefazodone.Investigational, Withdrawn
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Nefazodone.Approved, Investigational
VandetanibThe metabolism of Vandetanib can be decreased when combined with Nefazodone.Approved
VanoxerineThe metabolism of Vanoxerine can be decreased when combined with Nefazodone.Investigational
VardenafilThe serum concentration of Vardenafil can be increased when it is combined with Nefazodone.Approved
VecuroniumThe serum concentration of Vecuronium can be decreased when it is combined with Nefazodone.Approved
VemurafenibThe serum concentration of Vemurafenib can be increased when it is combined with Nefazodone.Approved
VenetoclaxThe metabolism of Venetoclax can be decreased when combined with Nefazodone.Approved
VenlafaxineThe metabolism of Venlafaxine can be decreased when combined with Nefazodone.Approved
VerapamilThe metabolism of Verapamil can be decreased when combined with Nefazodone.Approved
VicrivirocThe metabolism of Vicriviroc can be decreased when combined with Nefazodone.Investigational
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Nefazodone.Approved
VilanterolThe metabolism of Vilanterol can be decreased when combined with Nefazodone.Approved
VilazodoneThe serum concentration of Vilazodone can be increased when it is combined with Nefazodone.Approved
VildagliptinThe serum concentration of Nefazodone can be increased when it is combined with Vildagliptin.Approved, Investigational
VinblastineThe metabolism of Vinblastine can be decreased when combined with Nefazodone.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Nefazodone.Approved, Investigational
VincristineThe metabolism of Vincristine can be decreased when combined with Nefazodone.Approved, Investigational
VindesineThe serum concentration of Vindesine can be increased when it is combined with Nefazodone.Approved
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Nefazodone.Approved, Investigational
VismodegibThe metabolism of Vismodegib can be decreased when combined with Nefazodone.Approved
VorapaxarThe serum concentration of Vorapaxar can be increased when it is combined with Nefazodone.Approved
VoriconazoleThe metabolism of Nefazodone can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Nefazodone.Approved
WarfarinThe metabolism of Warfarin can be decreased when combined with Nefazodone.Approved
XimelagatranThe serum concentration of Nefazodone can be increased when it is combined with Ximelagatran.Approved, Investigational, Withdrawn
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Nefazodone.Vet Approved
Ym150The serum concentration of Nefazodone can be increased when it is combined with Ym150.Investigational
YohimbineThe metabolism of Yohimbine can be decreased when combined with Nefazodone.Approved, Vet Approved
ZafirlukastThe metabolism of Zafirlukast can be decreased when combined with Nefazodone.Approved, Investigational
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Nefazodone.Approved
ZaleplonThe metabolism of Zaleplon can be decreased when combined with Nefazodone.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Nefazodone.Approved
ZidovudineThe metabolism of Zidovudine can be decreased when combined with Nefazodone.Approved
ZileutonThe metabolism of Zileuton can be decreased when combined with Nefazodone.Approved, Investigational, Withdrawn
ZimelidineNefazodone may increase the serotonergic activities of Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Ziprasidone can be decreased when combined with Nefazodone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Nefazodone.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Nefazodone.Approved, Investigational
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Nefazodone.Approved
ZomepiracThe metabolism of Zomepirac can be decreased when combined with Nefazodone.Withdrawn
ZonisamideThe metabolism of Zonisamide can be decreased when combined with Nefazodone.Approved, Investigational
ZopicloneThe serum concentration of Zopiclone can be increased when it is combined with Nefazodone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Nefazodone is combined with Zotepine.Approved
ZuclopenthixolThe serum concentration of Zuclopenthixol can be increased when it is combined with Nefazodone.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Avoid avocado.
  • Limit garlic, ginger, gingko, and horse chestnut.
  • Take this medication either consistently with or without food as instructed by your doctor.
References
Synthesis Reference

DrugSyn.org

US4338317
General References
  1. Davis R, Whittington R, Bryson HM: Nefazodone. A review of its pharmacology and clinical efficacy in the management of major depression. Drugs. 1997 Apr;53(4):608-36. [PubMed:9098663 ]
External Links
ATC CodesN06AX06
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (152 KB)
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9744
Caco-2 permeable+0.5296
P-glycoprotein substrateSubstrate0.5809
P-glycoprotein inhibitor IInhibitor0.8564
P-glycoprotein inhibitor IIInhibitor0.8373
Renal organic cation transporterInhibitor0.5685
CYP450 2C9 substrateNon-substrate0.7898
CYP450 2D6 substrateNon-substrate0.9115
CYP450 3A4 substrateSubstrate0.7506
CYP450 1A2 substrateNon-inhibitor0.7931
CYP450 2C9 inhibitorInhibitor0.5999
CYP450 2D6 inhibitorNon-inhibitor0.8799
CYP450 2C19 inhibitorNon-inhibitor0.5434
CYP450 3A4 inhibitorNon-inhibitor0.8711
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8028
Ames testNon AMES toxic0.5208
CarcinogenicityNon-carcinogens0.7388
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.9067 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.8749
hERG inhibition (predictor II)Inhibitor0.7288
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
TabletOral100 mg/1
TabletOral150 mg/1
TabletOral200 mg/1
TabletOral250 mg/1
TabletOral50 mg/1
TabletOral100 mg
TabletOral150 mg
TabletOral200 mg
TabletOral50 mg
Prices
Unit descriptionCostUnit
Nefazodone hcl 250 mg tablet1.82USD tablet
Nefazodone hcl 200 mg tablet1.78USD tablet
Nefazodone hcl 150 mg tablet1.75USD tablet
Nefazodone hcl 100 mg tablet1.72USD tablet
Nefazodone hcl 50 mg tablet1.68USD tablet
Serzone 100 mg tablet1.53USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point83.5 °CPhysProp
logP4.7Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0698 mg/mLALOGPS
logP3.71ALOGPS
logP4.65ChemAxon
logS-3.8ALOGPS
pKa (Strongest Basic)7.09ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area51.62 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity132.38 m3·mol-1ChemAxon
Polarizability51.85 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-0uk9-9846000000-49cb6e97c09a9e806dd5View in MoNA
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylpiperazines. These are compounds containing a phenylpiperazine skeleton, which consists of a piperazine bound to a phenyl group.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassDiazinanes
Sub ClassPiperazines
Direct ParentPhenylpiperazines
Alternative Parents
Substituents
  • N-arylpiperazine
  • Phenylpiperazine
  • Substituted aniline
  • Dialkylarylamine
  • Phenol ether
  • N-alkylpiperazine
  • Halobenzene
  • Chlorobenzene
  • Aniline
  • Alkyl aryl ether
  • Benzenoid
  • Monocyclic benzene moiety
  • Aryl halide
  • Aryl chloride
  • Heteroaromatic compound
  • 1,2,4-triazole
  • Azole
  • Tertiary aliphatic amine
  • Tertiary amine
  • Azacycle
  • Ether
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Amine
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Virus receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates...
Gene Name:
HTR2A
Uniprot ID:
P28223
Molecular Weight:
52602.58 Da
References
  1. Hidalgo R, Hertzberg MA, Mellman T, Petty F, Tucker P, Weisler R, Zisook S, Chen S, Churchill E, Davidson J: Nefazodone in post-traumatic stress disorder: results from six open-label trials. Int Clin Psychopharmacol. 1999 Mar;14(2):61-8. [PubMed:10220119 ]
  2. Meyer JH, Cho R, Kennedy S, Kapur S: The effects of single dose nefazodone and paroxetine upon 5-HT2A binding potential in humans using [18F]-setoperone PET. Psychopharmacology (Berl). 1999 Jun;144(3):279-81. [PubMed:10435395 ]
  3. Horton JC, Trobe JD: Akinetopsia from nefazodone toxicity. Am J Ophthalmol. 1999 Oct;128(4):530-1. [PubMed:10577608 ]
  4. Eckler JR, Rabin RA, Winter JC: Nefazodone in the rat: mimicry and antagonism of [-]-DOM-induced stimulus control. Pharmacol Biochem Behav. 2003 May;75(2):405-10. [PubMed:12873632 ]
  5. Avila A, Cardona X, Martin-Baranera M, Maho P, Sastre F, Bello J: Does nefazodone improve both depression and Parkinson disease? A pilot randomized trial. J Clin Psychopharmacol. 2003 Oct;23(5):509-13. [PubMed:14520130 ]
  6. Taylor DP, Carter RB, Eison AS, Mullins UL, Smith HL, Torrente JR, Wright RN, Yocca FD: Pharmacology and neurochemistry of nefazodone, a novel antidepressant drug. J Clin Psychiatry. 1995;56 Suppl 6:3-11. [PubMed:7649970 ]
  7. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
  8. Davis R, Whittington R, Bryson HM: Nefazodone. A review of its pharmacology and clinical efficacy in the management of major depression. Drugs. 1997 Apr;53(4):608-36. [PubMed:9098663 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-iodophenyl-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modul...
Gene Name:
HTR2C
Uniprot ID:
P28335
Molecular Weight:
51820.705 Da
References
  1. Millan MJ: Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies. Therapie. 2005 Sep-Oct;60(5):441-60. [PubMed:16433010 ]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Serotonin:sodium symporter activity
Specific Function:
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into the pre-synaptic terminal for re-utilization. Plays a key role in mediating regulation of the availability of serotonin to other receptors of serotonergic systems. Terminates the action of serotonin an...
Gene Name:
SLC6A4
Uniprot ID:
P31645
Molecular Weight:
70324.165 Da
References
  1. Owens MJ, Ieni JR, Knight DL, Winders K, Nemeroff CB: The serotonergic antidepressant nefazodone inhibits the serotonin transporter: in vivo and ex vivo studies. Life Sci. 1995;57(24):PL373-80. [PubMed:7475971 ]
  2. Narayan M, Anderson G, Cellar J, Mallison RT, Price LH, Nelson JC: Serotonin transporter-blocking properties of nefazodone assessed by measurement of platelet serotonin. J Clin Psychopharmacol. 1998 Feb;18(1):67-71. [PubMed:9472845 ]
  3. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821 ]
  4. Taylor DP, Carter RB, Eison AS, Mullins UL, Smith HL, Torrente JR, Wright RN, Yocca FD: Pharmacology and neurochemistry of nefazodone, a novel antidepressant drug. J Clin Psychiatry. 1995;56 Suppl 6:3-11. [PubMed:7649970 ]
  5. Davis R, Whittington R, Bryson HM: Nefazodone. A review of its pharmacology and clinical efficacy in the management of major depression. Drugs. 1997 Apr;53(4):608-36. [PubMed:9098663 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Beta-arrestin family members inhibit signaling via G pro...
Gene Name:
HTR1A
Uniprot ID:
P08908
Molecular Weight:
46106.335 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Norepinephrine:sodium symporter activity
Specific Function:
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A2
Uniprot ID:
P23975
Molecular Weight:
69331.42 Da
References
  1. Owens MJ, Ieni JR, Knight DL, Winders K, Nemeroff CB: The serotonergic antidepressant nefazodone inhibits the serotonin transporter: in vivo and ex vivo studies. Life Sci. 1995;57(24):PL373-80. [PubMed:7475971 ]
  2. Owen D, Du L, Bakish D, Lapierre YD, Hrdina PD: Norepinephrine transporter gene polymorphism is not associated with susceptibility to major depression. Psychiatry Res. 1999 Jul 30;87(1):1-5. [PubMed:10512149 ]
  3. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821 ]
  4. Taylor DP, Carter RB, Eison AS, Mullins UL, Smith HL, Torrente JR, Wright RN, Yocca FD: Pharmacology and neurochemistry of nefazodone, a novel antidepressant drug. J Clin Psychiatry. 1995;56 Suppl 6:3-11. [PubMed:7649970 ]
  5. Davis R, Whittington R, Bryson HM: Nefazodone. A review of its pharmacology and clinical efficacy in the management of major depression. Drugs. 1997 Apr;53(4):608-36. [PubMed:9098663 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Monoamine transmembrane transporter activity
Specific Function:
Amine transporter. Terminates the action of dopamine by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A3
Uniprot ID:
Q01959
Molecular Weight:
68494.255 Da
References
  1. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
other/unknown
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine (PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1B
Uniprot ID:
P35368
Molecular Weight:
56835.375 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  3. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Thioesterase binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianser...
Gene Name:
ADRA2A
Uniprot ID:
P08913
Molecular Weight:
48956.275 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1A
Uniprot ID:
P35348
Molecular Weight:
51486.005 Da
References
  1. Taylor DP, Carter RB, Eison AS, Mullins UL, Smith HL, Torrente JR, Wright RN, Yocca FD: Pharmacology and neurochemistry of nefazodone, a novel antidepressant drug. J Clin Psychiatry. 1995;56 Suppl 6:3-11. [PubMed:7649970 ]
  2. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Davis R, Whittington R, Bryson HM: Nefazodone. A review of its pharmacology and clinical efficacy in the management of major depression. Drugs. 1997 Apr;53(4):608-36. [PubMed:9098663 ]
  2. DeVane CL, Donovan JL, Liston HL, Markowitz JS, Cheng KT, Risch SC, Willard L: Comparative CYP3A4 inhibitory effects of venlafaxine, fluoxetine, sertraline, and nefazodone in healthy volunteers. J Clin Psychopharmacol. 2004 Feb;24(1):4-10. [PubMed:14709940 ]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  4. von Moltke LL, Greenblatt DJ, Granda BW, Grassi JM, Schmider J, Harmatz JS, Shader RI: Nefazodone, meta-chlorophenylpiperazine, and their metabolites in vitro: cytochromes mediating transformation, and P450-3A4 inhibitory actions. Psychopharmacology (Berl). 1999 Jul;145(1):113-22. [PubMed:10445380 ]
  5. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. von Moltke LL, Greenblatt DJ, Granda BW, Grassi JM, Schmider J, Harmatz JS, Shader RI: Nefazodone, meta-chlorophenylpiperazine, and their metabolites in vitro: cytochromes mediating transformation, and P450-3A4 inhibitory actions. Psychopharmacology (Berl). 1999 Jul;145(1):113-22. [PubMed:10445380 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Not Available
Gene Name:
CYP2B
Uniprot ID:
Q14097
Molecular Weight:
43147.81 Da
References
  1. Haduch A, Wojcikowski J, Daniel WA: Effect of selected antidepressant drugs on cytochrome P450 2B (CYP2B) in rat liver. An in vitro and in vivo study. Pharmacol Rep. 2008 Nov-Dec;60(6):957-65. [PubMed:19211989 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Stormer E, von Moltke LL, Perloff MD, Greenblatt DJ: P-glycoprotein interactions of nefazodone and trazodone in cell culture. J Clin Pharmacol. 2001 Jul;41(7):708-14. [PubMed:11452702 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23